Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 2:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 308 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Moxifloxacin (Avelox, BAY12-8039) Clear all
Completed No phase listed Observational Results available

A 6-month Observational Study on Combined Oral Contraceptives and Body Weight in Pre-Menopausal Women With Overweight or Obesity

NCT05061472
View directory record Official record
Conditions
Contraceptive Usage, Overweight or Obesity, Body Weight Changes, Appetitive Behavior, Eating Behavior
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
20 participants
Timeline
2022 – 2023
U.S. locations
2
States / cities
Aurora, Colorado • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 11, 2024 · Synced Oct 9, 2026, 2:44 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Carbetocin on the QT/QTc Interval in Healthy Subjects

NCT05924321
View directory record Official record
Conditions
Postpartum Hemorrhage
Interventions
Carbetocin, Placebo, Placebo and Moxifloxacin
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 3, 2024 · Synced Oct 9, 2026, 2:44 PM EDT
Terminated Phase 2 Interventional Results available

Efficacy of Oral Antibiotic Therapy Compared to Intravenous Antibiotic Therapy for Osteomyelitis

NCT02168816
View directory record Official record
Conditions
Osteomyelitis
Interventions
Intravenous Antibacterial Agent, Oral Antibacterial Agent
Drug
Lead sponsor
Loyola University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 19, 2018 · Synced Oct 9, 2026, 2:44 PM EDT
Completed Phase 2 Interventional

TBTC Study 28: Moxifloxacin Versus Isoniazid for TB Treatment

NCT00144417
View directory record Official record
Conditions
Tuberculosis
Interventions
Moxifloxacin (with rifampin, pyrazinamide, and ethambutol), isoniazid
Drug
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years and older
Enrollment
433 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
20
States / cities
Little Rock, Arkansas • Los Angeles, California • San Diego, California + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2011 · Synced Oct 9, 2026, 2:44 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating the Effect of ETX2514 on Cardiac Repolarization in Healthy Male or Female Volunteers

NCT03985410
View directory record Official record
Conditions
Acinetobacter Baumannii-calcoaceticus Complex Infections
Interventions
ETX2514, Placebo, moxifloxacin
Drug
Lead sponsor
Entasis Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 30, 2019 · Synced Oct 9, 2026, 2:44 PM EDT
Completed Phase 3 Interventional

Intermittent Moxifloxacin Therapy For The Prevention Of Acute Exacerbations In Patients With Chronic Bronchitis

NCT00473460
View directory record Official record
Conditions
Lung Diseases, Bronchitis, Chronic
Interventions
Avelox (Moxifloxacin, BAY12-8039), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
45 Years to 90 Years
Enrollment
1,404 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
11
States / cities
Tucson, Arizona • Long Beach, California • Los Angeles, California + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2014 · Synced Oct 9, 2026, 2:44 PM EDT
Completed Phase 3 Interventional

AL-15469A for the Treatment of Bacterial Conjunctivitis

NCT00332293
View directory record Official record
Conditions
Bacterial Conjunctivitis
Interventions
Moxifloxacin Alternative Formulation Ophthalmic Solution 0.5%, Moxifloxacin hydrochloride ophthalmic solution 0.5% as base
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
1 Month and older
Enrollment
695 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Nov 18, 2016 · Synced Oct 9, 2026, 2:44 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Cardiac Safety of Oritavancin in Healthy Participants

NCT01762839
View directory record Official record
Conditions
Healthy
Interventions
Single-Dose IV Oritavancin Diphosphate, Placebo, Moxifloxacin
Drug
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 1, 2024 · Synced Oct 9, 2026, 2:44 PM EDT
Terminated Phase 3 Interventional

Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant

NCT00324324
View directory record Official record
Conditions
Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Infection, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
Interventions
moxifloxacin hydrochloride, Placebo
Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Oct 9, 2026, 2:44 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect on the Electrocardiographic QT Interval Corrected for Heart Rate (QTc) in Healthy Subjects

NCT00979316
View directory record Official record
Conditions
Alzheimer Disease
Interventions
BMS-708163, Placebo, Moxifloxacin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 7, 2011 · Synced Oct 9, 2026, 2:44 PM EDT
Completed Phase 4 Interventional Results available

Topical Treatment of Bacterial Conjunctivitis and Its Effect on Microbial Flora

NCT00312338
View directory record Official record
Conditions
Bacterial Conjunctivitis
Interventions
VIGAMOX
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
1 Year to 13 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Nov 2, 2012 · Synced Oct 9, 2026, 2:44 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers

Genetics of QT Response to Moxifloxacin

NCT01936480
View directory record Official record
Conditions
Cardiac Arrhythmias
Interventions
Moxifloxacin 400mg once time
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 12, 2022 · Synced Oct 9, 2026, 2:44 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Side Effect Profiles of Brand Name Versus Generic Oral Contraceptives

NCT00775190
View directory record Official record
Conditions
Contraception
Interventions
ortho tricyclen, Trinessa
Drug
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Oct 9, 2026, 2:44 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of PA-824 and of PA-824 Plus Moxifloxacin on the QTc Interval in Healthy Volunteers

NCT01674218
View directory record Official record
Conditions
Tuberculosis
Interventions
Moxifloxacin, PA-824, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 14, 2014 · Synced Oct 9, 2026, 2:44 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Ocular Availability in Human Tears After Topical Administration of 1.5% Levofloxacin Compared to Active Comparators

NCT00703313
View directory record Official record
Conditions
Healthy
Interventions
1.5% levofloxacin ophthalmic solution, 0.5% moxifloxacin hydrochloride ophthalmic solution, 0.3% gatifloxacin ophthalmic solution
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2008
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 6, 2009 · Synced Oct 9, 2026, 2:44 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Volanesorsen on Cardiac Repolarization Conducted in Healthy Volunteers

NCT02910635
View directory record Official record
Conditions
Abnormalities, Cardiovascular
Interventions
Volanesorsen, Moxifloxacin, Placebo
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 28, 2022 · Synced Oct 9, 2026, 2:44 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Oral Contraceptives, Insulin Resistance and Cardiovascular Risk Profile in Pre-Menopausal Women

NCT01475513
View directory record Official record
Conditions
Insulin Sensitivity, Cardiovascular Risk, Perimenopausal Disorder
Interventions
Ortho Cyclen®
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 8, 2018 · Synced Oct 9, 2026, 2:44 PM EDT
Terminated Phase 4 Interventional

Ocular Penetration of 1.5% Levofloxacin and 0.5% Moxifloxacin During Corneal Transplant Surgery

NCT00764582
View directory record Official record
Conditions
Corneal Transplantation
Interventions
1.5% levofloxacin ophthalmic solution, 0.5% moxifloxacin ophthalmic solution
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
8
States / cities
Boynton Beach, Florida • Indianapolis, Indiana • Great Rapids, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2009 · Synced Oct 9, 2026, 2:44 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Two-part, Single-dose, Randomized Study to Evaluate the Safety of Supra-therapeutic Doses of RO7033877 and to Investigate the Effect of RO7033877 on the QTc Interval

NCT02165332
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Part 1: SAD RO7033877, Part 1: SAD placebo, Part 2: Treatment A, RO7033877, Part 2: Treatment B, RO7033877, Part 2: Treatment C, moxifloxacin, Part 2: Treatment D, RO7033877 and moxifloxacin placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 9, 2026, 2:44 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Examine the Effect of HKI-272 on Rhythms of the Heart (Cardiac Repolarization)

NCT00708903
View directory record Official record
Conditions
Breast Cancer
Interventions
neratinib, Placebo, Moxifloxacin
Drug · Other
Lead sponsor
Puma Biotechnology, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated May 14, 2012 · Synced Oct 9, 2026, 2:44 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Double-Blind Study in Healthy Volunteers to Assess the Effect of E7080 on the QTc Interval

NCT01525394
View directory record Official record
Conditions
Refractory Solid Tumors, Lymphomas
Interventions
Lenvatinib, Moxifloxacin 400 mg, Placebos (matched to 4 mg and 10 mg lenvatinib capsules).
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2010
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 9, 2026, 2:44 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Clinical Trial to Evaluate the Effect of Ulonivirine (MK-8507) on Heart Rhythm in Healthy Adults (MK-8507-012)

NCT07305831
View directory record Official record
Conditions
Healthy
Interventions
Ulonivirine, Moxifloxacin, Ulonivirine Placebo, Moxifloxacin Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 9, 2026, 2:44 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Effect of Aficamten Administration on QT/QTc Interval

NCT05924815
View directory record Official record
Conditions
Healthy Participants
Interventions
Aficamten, Aficamten-matching Placebo, Moxifloxacin
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
18 Years to 45 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 19, 2023 · Synced Oct 9, 2026, 2:44 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Effect of Selpercatinib (LY3527723) on Corrected QT (QTc) Interval in Healthy Participants

NCT05630274
View directory record Official record
Conditions
Healthy
Interventions
Selpercatinib, Moxifloxacin, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Oct 9, 2026, 2:44 PM EDT